Prevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA - PubMed
4 days ago
- #cancer risk
- #BRCA1 methylation
- #cfDNA
- BRCA1 promoter methylation (BRCA1meth) is found in 20%-27% of triple-negative breast cancer (TNBC) and ovarian cancer (OvCa).
- BRCA1meth is detectable in peripheral blood cells of unaffected women, indicating increased cancer risk.
- The GRAIL cfDNA-based platform accurately detects BRCA1meth with a sensitivity of 0.0081 LoD95.
- cfBRCA1meth prevalence in noncancer individuals is 4.1%, higher in females (4.8%) than males (2.9%).
- In cancer patients, cfBRCA1meth is enriched in TNBC (15.2%) and OvCa (13.9%).
- cfBRCA1meth levels correlate with tumor burden in BRCA1meth-positive cancers.
- The GRAIL assay offers a single platform for assessing BRCA1meth in cancer risk and therapy response.